Search Bar & Filters
Found 53 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new treatment approach for people with metastatic pancreatic ductal adenocarcinoma PDAC who have progressed after initial therapy with certain chemotherapy combinations. The study focuses on assessing the safety, tolerability, and overall survival when adding an experimental therapy called E-EDV-D682GC to standard chemotherapy drugs gemcitabine and nab-paclitaxel. This trial is a randomized, blinded Phase IIIa study designed to compare this combination against gemcitabine and nab-paclitaxel alone. The experimental treatment includes two investigational products E-EDV-D682, which packages a chemotherapy agent targeted to cancer cells expressing EGFR, and EDV-GC, which aims to boost the bodys immune response. Participants receive these drugs alongside gemcitabine and nab-paclitaxel. The trial has two parts an initial safety phase with at least six participants receiving the experimental combination to check for side effects, followed by a randomized phase where participants are assigned either to the experimental combination or to standard chemotherapy with placebo. Treatment cycles involve bi-weekly then weekly visits, with tumor assessments every 8 weeks to monitor response. Participants will be involved for about six months, including screening, treatment, and follow-up. They will undergo regular clinical visits, imaging scans to measure tumor burden, and safety assessments throughout the study and for up to 30 days after treatment ends. Researchers will monitor adverse events and overall survival, as well as measure disease progression and response using established imaging criteria. The study also includes a safety follow-up period to closely track participants health after treatment.
Actively Recruiting
Researchers are conducting the TEMPUS AQUARIUS Study, an observational, long-term research focused on patients with blood cancers such as Acute Myeloid Leukemia AML and Follicular Lymphoma FL. The study aims to discover molecular biomarkers by collecting detailed molecular and clinical data to better understand how these markers relate to real-world patient outcomes. This study is sponsored by Tempus AI and follows patients over several years. Participants are grouped into cohorts based on their diagnosis and disease status, including newly diagnosed AML patients and various subgroups of FL patients distinguished by disease stage and risk. The study involves collecting samples like blood, leftover tissue, and bone marrow during patients regular medical care without any additional interventions. This approach allows researchers to observe and analyze disease progression and treatment effects through routine clinical monitoring. Participants will be involved over a period of up to five years, during which molecular and clinical data are gathered from biospecimens and medical records. The primary measurement is the assessment of biomarker patterns in disease progression and baseline samples, correlated with clinical outcomes. There are no study treatments to receive, and participation involves providing consent and biospecimens during their regular care visits.
Actively Recruiting
Researchers are evaluating NRM-823, a bispecific T-Cell Engager drug, in people with locally advanced or metastatic solid tumors including various types such as NSCLC, TNBC, HNSCC, ESCC, esophageal adenocarcinoma, gastricGEJ adenocarcinoma, cervical, endometrial, and ovarian cancers. This Phase 1 study aims to assess the safety and tolerability of NRM-823 alone and in combination with an immune checkpoint inhibitor. The study is sponsored by Normunity AccelCo, Inc. and focuses on treatment for refractory solid tumors. The study has three parts Part A evaluates safety and tolerability of NRM-823 Part B further assesses safety and tolerability of the recommended dose from Part A in an expanded group Part C tests the combination of NRM-823 with a checkpoint inhibitor. Treatment is given according to the study protocol, with participants receiving NRM-823 either alone or with the checkpoint inhibitor in Part C. Participants will be monitored from enrollment through 30 days after their last dose to track treatment-emergent adverse events and dose-limiting toxicities. They must have adequate organ function and performance status before starting. Safety and tolerability assessments will guide dosing and treatment continuation. The study is expected to complete by October 31, 2028.
Actively Recruiting
Researchers are evaluating an investigational drug called TS-104 in adults with select advanced solid tumors that have not improved with previous treatments. This Phase 1 study aims to determine a safe dose, understand side effects, assess how the drug is processed in the body, and evaluate its potential to treat these cancers. The study focuses on tumors like non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal, gastric, ovarian, and endometrial cancers. TS-104 is a peptide-drug conjugate designed to deliver the anticancer drug monomethyl auristatin E MMAE directly to tumor cells by targeting specific integrins commonly found on solid tumors. The study has two parts a dose escalation phase where researchers gradually increase doses to find the right level, and a dose expansion phase where one or more doses are tested in more participants. TS-104 is given either twice every three weeks or once every two weeks in treatment cycles lasting 21 or 28 days. Participants will receive TS-104 on one of these dosing schedules and will be closely monitored through regular assessments including scans and lab tests to track tumor response and side effects. Researchers will measure adverse events, dose-limiting toxicities, tumor response rates, progression-free survival, and overall survival, with follow-up continuing up to 26 months. The study is designed to carefully observe how participants tolerate the drug and how their cancer responds over time.
Actively Recruiting
Researchers are evaluating the safety and appropriate dosing of TRI-611, an oral ALK molecular glue degrader, in adults with ALK-positive non-small cell lung cancer NSCLC. This Phase 12 study also aims to understand how well TRI-611 works against tumors in this patient group. The study includes two parts first, testing different doses to find the best dose, and second, assessing the drugs effect in three groups based on prior treatments with ALK tyrosine kinase inhibitors TKIs. Participants will take TRI-611 continuously as long as their disease does not worsen and the treatment is tolerable. The study has four groups part 1 focuses on dose escalation and expansion, and part 2 includes cohorts defined by prior exposure to ALK TKIs, including lorlatinib and neladalkib. Visits occur approximately seven times during the first three months and then once at the start of each 28-day cycle thereafter. Participants will keep a diary to record each dose of the study medication. During the trial, participants will be monitored for side effects within 28 days after the first dose and have tumor responses evaluated about 16 weeks after dosing ends. Additional assessments include measuring drug levels in the blood and various long-term outcomes such as duration of response, disease control, progression-free survival, and overall survival, with follow-up lasting up to five years. Safety and tumor protein changes will also be observed to better understand TRI-611s effects.
Actively Recruiting
Researchers are evaluating the safety, dosage, and preliminary antitumor effects of Pocenbrodib alone and combined with darolutamide in men with metastatic castration-resistant prostate cancer mCRPC who have progressed after prior therapies including potent anti-androgen treatments. This Phase 1b2a open-label study includes dose escalation and optimization to find the maximum tolerated dose and recommended Phase 2 doses of Pocenbrodib, both as monotherapy and in combination with darolutamide. The study has three arms in Phase 1b Pocenbrodib given once daily 5 days on2 days off, Pocenbrodib given twice daily continuously, and Pocenbrodib combined with darolutamide twice daily continuously as a safety run-in for combination therapy. Phase 2a further evaluates the combination in two cohorts receiving different recommended doses of Pocenbrodib plus darolutamide after progression following lutetium-Lu-177-vipivotide-tetraxetan PLUVICTO and before taxane chemotherapy. Safety is closely monitored throughout. Participants will undergo assessments including safety and tolerability checks, pharmacokinetic and pharmacodynamic measurements, and evaluations of antitumor activity over treatment cycles of 28 days, estimated up to six months. Laboratory tests, imaging, and prostate-specific antigen PSA measurements will be collected to assess responses. Monitoring for adverse events and dose optimization guides treatment throughout the study duration until disease progression or discontinuation.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
1-10 of 53
1